TY - JOUR
T1 - Ex vivo transfection of transforming growth factor-β1 gene to pulmonary artery segments in lung grafts
AU - Yano, M.
AU - Mora, B. N.
AU - Ritter, J. M.
AU - Scheule, R. K.
AU - Yew, N. S.
AU - Mohanakumar, T.
AU - Patterson, G. A.
AU - Robbins, R. C.
N1 - Funding Information:
Supported by National Institutes of Health grant 1R0l HL-41281.
PY - 1999
Y1 - 1999
N2 - Objective: Proximal pulmonary artery segment transfection may provide beneficial downstream effects on the whole-lung graft. In this study, transforming growth factor-β1 was transfected to proximal pulmonary artery segments, and the efficacy of transforming growth factor-β1 transfection was examined in ischemia-reperfusion injury and acute rejection models of rat lung transplantation. Methods: In the ischemia-reperfusion injury model, orthotopic left lung transplantation was performed in F344 rats. In group I, the PPAS was isolated and injected with saline solution. In 2 other groups, lipid67:DOPE:sense (group H) or antisense transforming growth factor-β1pDNA construct (group III) was injected instead of saline solution. After cold preservation at 4°C for 18 hours, lung grafts were implanted. Graft function was assessed 24 hours later. In the acute rejection model, donor lung grafts were harvested. Proximal pulmonary artery segments were injected with saline solution (group I) or sense (group II) or antisense lipid gene construct (group III) and then implanted. Graft function was assessed on postoperative day 5. Results: In the ischemia, reperfusion injury study, there were no significant differences in oxygenation, wet-to-dry weight ratios, graft myeloperoxidase activity, or transforming growth factor-β1 levels in platelet-poor serum or proximal pulmonary artery segment homogenates. In the acute rejection study, oxygenation was significantly improved in group II receiving transforming growth factor-β1 (group II vs I and III, 136.0 ± 32.5 vs 54.0 ± 9.6 mm Hg and 53.8 ± 14.8 mm Hg; P = .016 and .016). There were no significant pathologic differences. Transforming growth factor-β1 concentrations from proximal pulmonary artery segment homogenates in group II were significantly higher compared with controls. Conclusions: Ex vivo transfection of transforming growth factor-β1 to proximal pulmonary artery segments did not affect reperfusion injury of lung isografts. In acute rejection, however, ex vivo transfection of transforming growth factor-β1 to proximal pulmonary artery segments improved allograft function. This suggests that transfection to proximal pulmonary artery segments exerts beneficial downstream effects on the whole-lung allograft.
AB - Objective: Proximal pulmonary artery segment transfection may provide beneficial downstream effects on the whole-lung graft. In this study, transforming growth factor-β1 was transfected to proximal pulmonary artery segments, and the efficacy of transforming growth factor-β1 transfection was examined in ischemia-reperfusion injury and acute rejection models of rat lung transplantation. Methods: In the ischemia-reperfusion injury model, orthotopic left lung transplantation was performed in F344 rats. In group I, the PPAS was isolated and injected with saline solution. In 2 other groups, lipid67:DOPE:sense (group H) or antisense transforming growth factor-β1pDNA construct (group III) was injected instead of saline solution. After cold preservation at 4°C for 18 hours, lung grafts were implanted. Graft function was assessed 24 hours later. In the acute rejection model, donor lung grafts were harvested. Proximal pulmonary artery segments were injected with saline solution (group I) or sense (group II) or antisense lipid gene construct (group III) and then implanted. Graft function was assessed on postoperative day 5. Results: In the ischemia, reperfusion injury study, there were no significant differences in oxygenation, wet-to-dry weight ratios, graft myeloperoxidase activity, or transforming growth factor-β1 levels in platelet-poor serum or proximal pulmonary artery segment homogenates. In the acute rejection study, oxygenation was significantly improved in group II receiving transforming growth factor-β1 (group II vs I and III, 136.0 ± 32.5 vs 54.0 ± 9.6 mm Hg and 53.8 ± 14.8 mm Hg; P = .016 and .016). There were no significant pathologic differences. Transforming growth factor-β1 concentrations from proximal pulmonary artery segment homogenates in group II were significantly higher compared with controls. Conclusions: Ex vivo transfection of transforming growth factor-β1 to proximal pulmonary artery segments did not affect reperfusion injury of lung isografts. In acute rejection, however, ex vivo transfection of transforming growth factor-β1 to proximal pulmonary artery segments improved allograft function. This suggests that transfection to proximal pulmonary artery segments exerts beneficial downstream effects on the whole-lung allograft.
UR - http://www.scopus.com/inward/record.url?scp=0032913453&partnerID=8YFLogxK
U2 - 10.1016/S0022-5223(99)70290-4
DO - 10.1016/S0022-5223(99)70290-4
M3 - Article
C2 - 10096965
AN - SCOPUS:0032913453
SN - 0022-5223
VL - 117
SP - 705
EP - 713
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
IS - 4
ER -